18889881171
Kalkine 0
countryflagUS
Login

AAPL 189.1 -6.9344% MSFT 361.17 -3.2001% NVDA 93.9716 -7.69% GOOGL 147.225 -2.3189% GOOG 149.2 -2.2473% AMZN 173.59 -2.7016% META 506.8 -4.6687% AVGO 148.55 -3.5452% LLY 738.02 -6.472% TSLA 239.865 -10.257% TSM 146.085 -7.1769% V 316.3 -6.8034% JPM 211.125 -7.1121% UNH 529.505 -2.0234% NVO 62.66 -6.617% WMT 83.2 -4.6528% LVMUY 114.68 -4.497% XOM 105.06 -6.5552% LVMHF 575.0 -4.485% MA 496.24 -6.4669%
AAPL 189.1 -6.9344% MSFT 361.17 -3.2001% NVDA 93.9716 -7.69% GOOGL 147.225 -2.3189% GOOG 149.2 -2.2473% AMZN 173.59 -2.7016% META 506.8 -4.6687% AVGO 148.55 -3.5452% LLY 738.02 -6.472% TSLA 239.865 -10.257% TSM 146.085 -7.1769% V 316.3 -6.8034% JPM 211.125 -7.1121% UNH 529.505 -2.0234% NVO 62.66 -6.617% WMT 83.2 -4.6528% LVMUY 114.68 -4.497% XOM 105.06 -6.5552% LVMHF 575.0 -4.485% MA 496.24 -6.4669%

Rocket Pharmaceuticals Inc

Healthcare US RCKT

5.185USD
-0.375(6.74%)

Last update at 2025-04-04T18:51:00Z

Day Range

5.125.43
LowHigh

52 Week Range

14.8932.52
LowHigh

Fundamentals

  • Previous Close 5.56
  • Market Cap1900.98M
  • Volume3477583
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-257.16099M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.85

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

2018-12-312019-12-312020-12-312021-12-312022-12-31-200M-180M-160M-140M-120M-100M-80M-60M-40M-20M0M
Total Revenue
Net Income

Balancesheet

2019-12-312020-12-312021-12-312022-12-312023-12-310M50M100M150M200M250M300M350M400M450M500M550M
Total Assets
Total Liabilities

Change in Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31-80M-60M-40M-20M0M20M40M60M80M100M

Total Operating Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31-180M-170M-160M-150M-140M-130M-120M-110M-100M-90M-80M-70M-60M-50M

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -221.86300M -169.06900M -139.70000M -77.27000M -74.51800M
Minority interest - - - - -
Net income -219.38300M -169.58500M -146.66700M -83.22800M -74.51800M
Selling general administrative 58.77M 41.77M 27.92M 17.53M 17.89M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 6.27M 5.37M 1.15M 0.43M 0.33M
Ebit -224.34300M -167.24800M -134.30300M -76.15100M -69.28000M
Ebitda -213.68800M -163.18000M -131.00800M -72.06100M -68.95000M
Depreciation and amortization 10.65M 4.07M 3.29M 4.09M 0.33M
Non operating income net other - 0.16M 1.57M 4.59M 2.49M
Operating income -224.34300M -167.24800M -134.30300M -76.15100M -71.15600M
Other operating expenses 223.84M 166.25M 134.30M 75.90M 70.97M
Interest expense 1.91M 5.89M 7.55M 4.78M 5.24M
Tax provision - - - - -
Interest income 3.89M 3.07M 2.15M 3.41M 1.69M
Net interest income 1.98M -2.82100M -4.81700M -2.54400M -4.34900M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.48000M 0.52M 6.97M 5.96M 2.68M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 223.84M 166.25M 134.30M 75.90M 70.97M
Cost of revenue - - - - 0.00000M
Total other income expense net 2.48M -1.82100M -5.39700M -1.11900M 0.80M
Discontinued operations - - - - -
Net income from continuing ops -221.86300M -169.06900M -139.70000M -77.52000M -74.70400M
Net income applicable to common shares -221.86300M -169.06900M -139.70000M -77.27000M -74.51800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 566.34M 551.81M 497.02M 590.82M 372.12M
Intangible assets 25.15M 25.72M - - 0.23M
Earning assets - - - - -
Other current assets 5.05M 7.67M 3.32M 4.63M 3.64M
Total liab 73.77M 62.12M 42.30M 87.31M 64.82M
Total stockholder equity 492.57M 489.69M 454.72M 503.52M 307.30M
Deferred long term liab - - - - -
Other current liab 45.79M 36.66M 19.61M 24.88M 16.79M
Common stock 0.90M 0.79M 0.65M 0.61M 0.55M
Capital stock 0.90M 0.79M 0.65M 0.61M 0.55M
Retained earnings -959.37000M -713.77500M -491.91200M -322.84300M -183.14300M
Other liab - 2.60M 0.08M 0.14M 0.02M
Good will 39.15M 39.15M 30.82M 30.82M 30.82M
Other assets - 1.95M 497.02M 53.46M 1.98M
Cash 55.90M 140.52M 232.69M 297.10M 185.38M
Cash and equivalents - - - - -
Total current liabilities 48.51M 39.17M 22.17M 32.62M 18.31M
Current deferred revenue -0.00177M -36.66000M - 0.59M 0.56M
Net debt -30.86200M -117.65100M -210.09300M -235.40100M -137.93400M
Short term debt 2.72M 2.51M 2.55M 7.14M 0.96M
Short long term debt - - - 4.88M -
Short long term debt total 25.04M 22.87M 22.60M 61.70M 47.45M
Other stockholder equity 1450.72M 1203.03M 946.15M 825.79M 489.87M
Property plant equipment - 77.64M 72.35M 19.21M 29.30M
Total current assets 378.22M 364.06M 392.06M 487.35M 307.75M
Long term investments 34.32M 43.28M - - 0.00000M
Net tangible assets - 424.81M 454.84M 503.52M 307.30M
Short term investments 317.27M 215.88M 156.05M 185.62M 118.73M
Net receivables - - - - -
Long term debt - - - 35.07M 45.05M
Inventory - - - - -
Accounts payable 0.00177M 36.66M 0.48M 25.47M 17.35M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.32M -0.35700M -0.16100M -0.04200M 0.02M
Additional paid in capital - - - - -
Common stock total equity - - 0.65M 0.61M 0.55M
Preferred stock total equity - - - - -
Retained earnings total equity - - -491.91200M -322.84300M -183.14300M
Treasury stock - - - - -0.05300M
Accumulated amortization - - - - -
Non currrent assets other 1.37M 1.95M 1.80M 2.02M 1.98M
Deferred long term asset charges - - - - -
Non current assets total 188.12M 187.75M 104.96M 103.48M 64.37M
Capital lease obligations 25.04M 22.87M 22.60M 21.76M 2.40M
Long term debt total - - - 35.07M 45.05M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -69.32600M 26.57M -67.53200M -15.74200M -79.81100M
Change to liabilities 9.67M -4.82700M 11.13M -2.72200M 5.89M
Total cashflows from investing activities -69.32600M 18.85M -96.59100M -39.01100M -5.27200M
Net borrowings - - -0.23700M - -
Total cash from financing activities 155.29M 37.68M 282.99M 177.79M 153.50M
Change to operating activities -3.59800M 1.44M 4.01M -1.00400M -1.50500M
Net income -221.86300M -169.06900M -139.70000M -77.27000M -74.51800M
Change in cash -92.18000M -64.62900M 111.76M 74.12M 94.44M
Begin period cash flow 234.04M 298.67M 186.91M 112.79M 18.35M
End period cash flow 141.86M 234.04M 298.67M 186.91M 112.79M
Total cash from operating activities -178.14200M -121.16300M -74.64000M -64.66300M -53.78800M
Issuance of capital stock 154.70M 26.35M 281.35M 178.10M 154.02M
Depreciation 6.27M 5.37M 1.15M 0.43M 0.33M
Other cashflows from investing activities -0.26100M -0.09500M -8.45200M -15.74200M 75.99M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock -0.04700M 37.68M -0.07200M 0.73M -0.66800M
Other cashflows from financing activities 0.63M 11.33M 1.71M -1.03900M 0.15M
Change to netincome 31.38M 45.17M 45.13M 13.37M 13.92M
Capital expenditures 8.62M 7.71M 29.06M 23.27M 1.45M
Change receivables - - - - -
Cash flows other operating - 6.78M 4.90M -2.07000M -1.66600M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -64.62900M 111.76M 74.12M 94.44M
Change in working capital 6.08M -3.38600M 15.03M -3.72600M 4.38M
Stock based compensation 31.01M 29.24M 18.57M 13.37M 13.60M
Other non cash items 0.37M 13.53M 29.32M 3.60M 2.90M
Free cash flow -186.76100M -128.87800M -103.69900M -87.93200M -55.24100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
RCKT
Rocket Pharmaceuticals Inc		 -0.375 6.74% 5.18 - - - 4.44 -7.7734
NVO
Novo Nordisk A/S		 -4.44 6.62% 62.66 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.842 5.72% 63.30 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -5.74 1.19% 478.27 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -27.19 4.45% 583.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Rocket Pharmaceuticals Inc

9 Cedarbrook Drive, Cranbury, NJ, United States, 08512

Key Executives

Name Title Year Born
Dr. Gaurav D. Shah M.D. CEO & Director 1975
Ms. Kinnari Patel M.B.A., MBA, Pharm.D., PharmD Pres & COO 1979
Mr. Martin Louis Wilson J.D. Gen. Counsel, Chief Compliance Officer & Sr. VP 1976
Mr. Jonathan Schwartz Chief Medical Officer & Sr. VP of Clinical Devel. 1964
Mr. John C. Militello CPA, CPA Interim Principal Financial Officer, VP, Sr. Controller, Treasurer & Principal Accounting Officer 1973
Mr. Mayo Pujols Chief Technical Officer, Exec. VP & Director NA
Mayur Kasetty M.B.A., M.D. Bus. Devel. & Operations and Investor Relations Lead NA
Ms. Jessie Yeung M.B.A. VP of Investor Relations & Corp. Fin. NA
Kevin Giordano Director of Corp. Communications NA
Ms. Isabel Carmona J.D. Sr. VP & Chief HR Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.